Request Deal Involvement

Covis Pharma completed the acquisition of the global rights of Eklira and Duaklir from AstraZeneca for $270m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Buchanan Ingersoll & Rooney

legal advisors

Buchanan Ingersoll & Rooney

Sidley Austin

legal advisors

Sidley Austin

Fasken

legal advisors

Fasken

Barclays

financial advisors

Barclays

Paul Weiss Rifkind Wharton & Garrison

legal advisors

Paul Weiss Rifkind Wharton & Garrison

or

Principals

ASTRAZENECA PLC

vendor

ASTRAZENECA PLC

ASTRAZENECA PLC (EKLIRA AND DUAKLIR)

target

ASTRAZENECA PLC (EKLIRA AND DUAKLIR)

COVIS PHARMA

bidder

COVIS PHARMA

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Covis Pharma completed the acquisition of the global rights of Eklira and Duaklir from AstraZeneca for $270m.